John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 50,000 shares at $35.13 ($1.7M) on 2026-06-29, disclosed to the SEC on 2026-07-01.
Scheduled sale ($1.7M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.13 | 13,421 | $472K | 27.0% |
| 2 | $35.91 | 11,579 | $416K | 23.8% |
| 3 | $34.26 | 23,100 | $791K | 45.4% |
| 4 | $34.84 | 1,900 | $66K | 3.8% |
| Total | $34.90 avg | 50,000 | $1.7M | 100% |
| Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |
| BEAM | SELL | 2025-04-03 | $1.1M | — | Filing → |